We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Pfizer Inc | NYSE:PFE | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 27.18 | 0 | 01:00:00 |
From May 2019 to May 2024
By Alex MacDonald
LONDON--U.K.-listed pharmaceutical company AstraZeneca PLC on Tuesday said its pipeline of drugs is expected to drive strong and consistent revenue growth, delivering annual revenues in excess of $45 billion by 2023.
AstraZeneca, which earlier this year rejected a takeover approach from U.S.-based Pfizer Inc., said its business strategy is evolving to become more sustainable and profitable.
"We have more than doubled the number of potential medicines in our late-stage pipeline since 2012 and we are on track to return to growth by 2017," Chief Executive Pascal Soriot said in a news release ahead of an invest day presentation later Tuesday.
"Fueled by a very exciting portfolio of new products, oncology is set to become AstraZeneca's sixth growth platform and play a large part in supporting our efforts to bring life-changing medicines to patients as well as delivering long-term growth," he added.
Write to Alex MacDonald at alex.macdonald@wsj.com
Access Investor Kit for Pfizer Inc.
Visit http://www.companyspotlight.com/partner?cp_code=P479&isin=US7170811035
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Pfizer Chart |
1 Month Pfizer Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
